Martinino Alessandro, Bucaro Angela, Cardella Francesca, Wazir Ishaan, Frongillo Francesco, Ardito Francesco, Giovinazzo Francesco
Department of Surgery, Duke University, Durham, NC, United States.
General Surgery and Liver Transplant Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Front Oncol. 2024 Mar 18;14:1366607. doi: 10.3389/fonc.2024.1366607. eCollection 2024.
HCC is a major global health concern, necessitating effective treatment strategies. This study conducts a meta-analysis of meta-analyses comparing liver resection (LR) and liver transplantation (LT) for HCC.
The systematic review included meta-analyses comparing liver resection vs. liver transplantation in HCC, following PRISMA guidelines. Primary outcomes included 5-year overall survival (OS) and disease-free survival (DFS). AMSTAR-2 assessed study quality. Citation matrix and hierarchical clustering validated the consistency of the included studies.
A search identified 10 meta-analyses for inclusion. The median Pearson correlation coefficient for citations was 0.59 (IQR 0.41-0.65). LT showed better 5-year survival and disease-free survival in all HCC (OR): 0.79; 95% CI: 0.67-0.93, I^2:57% and OR: 0.44; 95% CI: 0.25-0.75, I^2:96%). Five-year survival in early HCC and ITT was 0.63 (95% CI: 0.50-0.78, I^2:0%) and 0.60 (95% CI: 0.39-0.92, I^2:0%). Salvage LT vs. Primary LT did not differ between 5-year survival and disease-free survival (OR: 0.62; 95% CI: 0.33-1.15, I^2:0% and 0.93; 95% CI: 0.82-1.04, I^2:0%).
Overall, the study underscores the superior survival outcomes associated with LT over LR in HCC treatment, supported by comprehensive meta-analysis and clustering analysis. There was no difference in survival or recurrence rate between salvage LT and primary LT. Therefore, considering the organ shortage, HCC can be resected and transplanted in case of recurrence.
肝癌是全球主要的健康问题,需要有效的治疗策略。本研究对比较肝癌肝切除术(LR)和肝移植术(LT)的荟萃分析进行了荟萃分析。
按照PRISMA指南进行系统评价,纳入比较肝癌肝切除术与肝移植术的荟萃分析。主要结局包括5年总生存率(OS)和无病生存率(DFS)。AMSTAR-2评估研究质量。引用矩阵和层次聚类验证了纳入研究的一致性。
检索到10项荟萃分析纳入研究。引用的中位数Pearson相关系数为0.59(四分位间距0.41 - 0.65)。在所有肝癌患者中,肝移植术的5年生存率和无病生存率更高(OR:0.79;95%CI:0.67 - 0.93,I²:57%;OR:0.44;95%CI:0.25 - 0.75,I²:96%)。早期肝癌和意向性分析人群的5年生存率分别为0.63(95%CI:0.50 - 0.78,I²:0%)和0.60(95%CI:0.39 - 0.92,I²:0%)。挽救性肝移植与初次肝移植在5年生存率和无病生存率方面无差异(OR:0.62;95%CI:0.33 - 1.15,I²:0%;OR:0.93;95%CI:0.82 - 1.04,I²:0%)。
总体而言,本研究通过全面的荟萃分析和聚类分析表明,在肝癌治疗中,肝移植术的生存结局优于肝切除术。挽救性肝移植与初次肝移植在生存率或复发率方面无差异。因此,考虑到器官短缺,肝癌复发时可进行切除和移植。